Betty J Dong

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women
    Betty J Dong
    University of California, San Francisco, 94143 0622, USA
    AIDS 26:833-41. 2012
  2. ncbi Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism
    Betty J Dong
    School of Pharmacy, University of California San Francisco, 521 Parnassus Avenue C 152, San Francisco, CA 94143 0622, USA
    Clin Ther 27:1725-51. 2005
  3. ncbi Tipranavir: a protease inhibitor for HIV salvage therapy
    Betty J Dong
    Department of Clinical Pharmacy, School of Pharmacy, University of California at San Francisco, 94143, USA
    Ann Pharmacother 40:1311-21. 2006
  4. ncbi Raltegravir: the first HIV integrase inhibitor
    Jennifer Cocohoba
    Department of Clinical Pharmacy, School of Pharmacy, University of California San Francisco, San Francisco, California 94143, USA
    Clin Ther 30:1747-65. 2008
  5. ncbi Immunologic benefits of enfuvirtide in patients enrolled in a drug assistance program
    Parya Saberi
    Department of Family and Community Medicine, University of California at San Francisco, San Francisco, CA 94143, USA
    Ann Pharmacother 42:621-6. 2008
  6. ncbi Health care provider satisfaction with telephone consultations provided by pharmacists and physicians at the National HIV/AIDS Clinicians' Consultation Center
    Elizabeth M Sherman
    Department of Clinical Pharmacy, University of California, San Francisco, CA, USA
    Ann Pharmacother 45:1499-505. 2011
  7. ncbi The impact of HIV clinical pharmacists on HIV treatment outcomes: a systematic review
    Parya Saberi
    Department of Medicine, University of California, San Francisco, CA, USA
    Patient Prefer Adherence 6:297-322. 2012
  8. ncbi Treatment of AIDS and HIV-related conditions--2002: antiretroviral therapy
    Ronald H Goldschrnidt
    Family Practice Residency Program, San Francisco General Hospital, University of California, San Francisco 94110, USA
    J Am Board Fam Pract 15:319-31. 2002
  9. ncbi Outcomes of dual-protease inhibitor salvage therapy in human immunodeficiency virus-infected patients referred to a telephone consultation service
    Michael L Lim
    National HIV Telephone Consultation Service, San Francisco General Hospital, California, USA
    Pharmacotherapy 23:1100-4. 2003
  10. ncbi Advances in human immunodeficiency virus therapeutics
    Patrick G Clay
    Kansas City University of Medicine and Biosciences, Kansas City, MO 64106, USA
    Ann Pharmacother 40:704-9. 2006

Detail Information

Publications10

  1. ncbi Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women
    Betty J Dong
    University of California, San Francisco, 94143 0622, USA
    AIDS 26:833-41. 2012
    ..To estimate nevirapine (NVP) pharmacokinetics and examine its association with rash and/or hepatotoxicity in women starting antiretroviral treatment in the AIDS Clinical Trials Group A5208/OCTANE study in Africa...
  2. ncbi Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism
    Betty J Dong
    School of Pharmacy, University of California San Francisco, 521 Parnassus Avenue C 152, San Francisco, CA 94143 0622, USA
    Clin Ther 27:1725-51. 2005
    ..Traditional medical therapy (eg, vitamin D sterols, calcium, phosphate binders) has been inadequate for the management of HPT and its vascular and skeletal complications...
  3. ncbi Tipranavir: a protease inhibitor for HIV salvage therapy
    Betty J Dong
    Department of Clinical Pharmacy, School of Pharmacy, University of California at San Francisco, 94143, USA
    Ann Pharmacother 40:1311-21. 2006
    ..To review the efficacy, safety, pharmacology, virology, pharmacokinetics, and resistance of the nonpeptidic protease inhibitor (PI) tipranavir...
  4. ncbi Raltegravir: the first HIV integrase inhibitor
    Jennifer Cocohoba
    Department of Clinical Pharmacy, School of Pharmacy, University of California San Francisco, San Francisco, California 94143, USA
    Clin Ther 30:1747-65. 2008
    ..Raltegravir is the first integrase inhibitor to be approved by the US Food and Drug Administration for use in antiretroviral treatment- experienced adult patients with viral resistance...
  5. ncbi Immunologic benefits of enfuvirtide in patients enrolled in a drug assistance program
    Parya Saberi
    Department of Family and Community Medicine, University of California at San Francisco, San Francisco, CA 94143, USA
    Ann Pharmacother 42:621-6. 2008
    ..Randomized clinical trials have demonstrated that enfuvirtide plus an optimized background regimen can cause a significant increase in CD4+ cell counts and a reduction in HIV RNA levels...
  6. ncbi Health care provider satisfaction with telephone consultations provided by pharmacists and physicians at the National HIV/AIDS Clinicians' Consultation Center
    Elizabeth M Sherman
    Department of Clinical Pharmacy, University of California, San Francisco, CA, USA
    Ann Pharmacother 45:1499-505. 2011
    ..Callers to the NCCC receive consultation from either a clinical pharmacist (PharmD) or a physician (MD) with HIV expertise...
  7. ncbi The impact of HIV clinical pharmacists on HIV treatment outcomes: a systematic review
    Parya Saberi
    Department of Medicine, University of California, San Francisco, CA, USA
    Patient Prefer Adherence 6:297-322. 2012
    ..In a HIV multidisciplinary care team, the HIV pharmacist is well-equipped to provide this expertise. We conducted a systematic review to assess the impact of HIV pharmacists on HIV clinical outcomes...
  8. ncbi Treatment of AIDS and HIV-related conditions--2002: antiretroviral therapy
    Ronald H Goldschrnidt
    Family Practice Residency Program, San Francisco General Hospital, University of California, San Francisco 94110, USA
    J Am Board Fam Pract 15:319-31. 2002
  9. ncbi Outcomes of dual-protease inhibitor salvage therapy in human immunodeficiency virus-infected patients referred to a telephone consultation service
    Michael L Lim
    National HIV Telephone Consultation Service, San Francisco General Hospital, California, USA
    Pharmacotherapy 23:1100-4. 2003
    ..To determine the clinical outcomes of dual-protease inhibitor salvage therapy in heavily experienced patients after their providers consulted the National HIV Telephone Consultation Service (Warmline, 800-933-3413)...
  10. ncbi Advances in human immunodeficiency virus therapeutics
    Patrick G Clay
    Kansas City University of Medicine and Biosciences, Kansas City, MO 64106, USA
    Ann Pharmacother 40:704-9. 2006
    ..To review recent advances in the management of persons infected with HIV...